Payment overview · 2025
General Payments
$1,581.09
94 reported records · 19 companies
Healthcare provider profile · identity verified
Edward J Miller, MD
Allopathic & Osteopathic Physicians|Internal Medicine · YOUNGSTOWN, OH · NPI 1891763355
Verified facts
What the public records show
CMS Open Payments records show Edward J Miller, MD received $1,581.09 in general payments during 2025 across 94 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 297 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 283 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 280 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $379.54 | 24.0% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $230.60 | 14.6% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $219.32 | 13.9% | 14 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $213.57 | 13.5% | 19 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $150.94 | 9.6% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.47 | 4.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.54 | 3.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.70 | 2.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $39.49 | 2.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $37.87 | 2.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.29 | 1.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.97 | 1.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.01 | 1.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.87 | 1.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.66 | 1.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.59 | 1.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.33 | 1.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.22 | 1.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.11 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,581.09 | 94 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $271.82 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $219.32 | 14 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $213.57 | 19 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $199.16 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $181.66 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $166.67 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $150.94 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $150.94 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $143.50 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $137.19 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $56.50 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.85 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $48.94 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $47.54 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $37.87 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $36.83 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 280 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 59 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 297 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 283 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 42 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 125 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
133 | 32 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | 16 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
125 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
297 | 58 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
283 | 46 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
280 | 54 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 876 | 233 |
| Levothyroxine Sodium | Levothyroxine Sodium | 874 | 201 |
| Amlodipine Besylate | Amlodipine Besylate | 703 | 180 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 650 | 183 |
| Metoprolol Succinate | Metoprolol Succinate | 607 | 156 |
| Pantoprazole Sodium | Pantoprazole Sodium | 454 | 116 |
| Lisinopril | Lisinopril | 408 | 116 |
| Metformin Hcl | Metformin Hcl | 338 | 91 |
| Losartan Potassium | Losartan Potassium | 311 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 298 | 80 |
| Jardiance | Empagliflozin | 297 | 58 |
| Valsartan | Valsartan | 286 | 76 |
| Ozempic | Semaglutide | 283 | 46 |
| Eliquis | Apixaban | 280 | 54 |
| Simvastatin | Simvastatin | 266 | 57 |
| Gabapentin | Gabapentin | 261 | 71 |
| Lorazepam | Lorazepam | 257 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 224 | 68 |
| Furosemide | Furosemide | 196 | 54 |
| Celecoxib | Celecoxib | 193 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 187 | 48 |
| Omeprazole | Omeprazole | 180 | 47 |
| Alprazolam | Alprazolam | 164 | 29 |
| Carvedilol | Carvedilol | 157 | 40 |
| Alendronate Sodium | Alendronate Sodium | 154 | 39 |
| Tramadol Hcl | Tramadol Hcl | 154 | 40 |
| Allopurinol | Allopurinol | 152 | 42 |
| Ezetimibe | Ezetimibe | 151 | 43 |
| Prednisone | Prednisone | 148 | 71 |
| Meloxicam | Meloxicam | 145 | 39 |
| Potassium Chloride | Potassium Chloride | 141 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 140 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 139 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 136 | 40 |
| Sertraline Hcl | Sertraline Hcl | 134 | 27 |
| Synthroid | Levothyroxine Sodium | 133 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 125 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 41 |
| Donepezil Hcl | Donepezil Hcl | 114 | 31 |
| Irbesartan | Irbesartan | 113 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 111 | 52 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 111 | 29 |
| Bumetanide | Bumetanide | 101 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 101 | 23 |
| Metformin Hcl Er | Metformin Hcl | 101 | 23 |
| Vascepa | Icosapent Ethyl | 101 | 13 |
| Bupropion Xl | Bupropion Hcl | 100 | 27 |
| Warfarin Sodium | Warfarin Sodium | 100 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 98 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 44 |
| Atenolol | Atenolol | 94 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 21 |
| Montelukast Sodium | Montelukast Sodium | 91 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 27 |
| Repatha Sureclick | Evolocumab | 84 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 20 |
| Clonazepam | Clonazepam | 78 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 22 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 75 | 19 |
| Trazodone Hcl | Trazodone Hcl | 68 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 65 | 15 |
| Pregabalin | Pregabalin | 62 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 19 |
| Meclizine Hcl | Meclizine Hcl | 61 | 25 |
| Diazepam | Diazepam | 60 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 60 | 16 |
| Digoxin | Digoxin | 59 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | 19 |
| Farxiga | Dapagliflozin Propanediol | 59 | 16 |
| Metolazone | Metolazone | 58 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 13 |
| Memantine Hcl Er | Memantine Hcl | 54 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 53 | 13 |
| Colchicine | Colchicine | 52 | 15 |
| Spironolactone | Spironolactone | 52 | 18 |
| Aripiprazole | Aripiprazole | 51 | suppressed |
| Cefdinir | Cefdinir | 51 | 43 |
| Benazepril Hcl | Benazepril Hcl | 50 | suppressed |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 37 |
| Mirtazapine | Mirtazapine | 45 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 45 | 11 |
| Finasteride | Finasteride | 44 | 14 |
| Rybelsus | Semaglutide | 42 | 12 |
| Azithromycin | Azithromycin | 41 | 38 |
| Ibuprofen | Ibuprofen | 40 | 14 |
| Levofloxacin | Levofloxacin | 40 | 35 |
| Phenobarbital | Phenobarbital | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 20 |
| Famotidine | Famotidine | 38 | 16 |
| Clarithromycin | Clarithromycin | 36 | 31 |
| Kerendia | Finerenone | 35 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Mupirocin | Mupirocin | 34 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | suppressed |
| Ketoconazole | Ketoconazole | 33 | 16 |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Naproxen | Naproxen | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Torsemide | Torsemide | 29 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Ibu | Ibuprofen | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 24 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 18 |
| Trulicity | Dulaglutide | 24 | suppressed |
| Keppra | Levetiracetam | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 15 |
| Glipizide | Glipizide | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 22 |
| Olanzapine | Olanzapine | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Sulfasalazine | Sulfasalazine | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 14 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Telmisartan | Telmisartan | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Epinephrine | Epinephrine | 13 | 11 |
| Indapamide | Indapamide | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,581.09 · 94 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, Korlym, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VYNDAMAX, Wegovy, XIFAXAN, ZAVZPRET, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error